AzTrials
AzTrials

High-Risk Surgical PatientsPhase 2NCT00254150

A Therapy to Reduce Morbidity and Hospital Length of Stay of High-Risk Surgical Patients

A Phase 2 study testing Increase oxygen extraction rate in people with High-Risk Surgical Patients, run by Università Politecnica delle Marche at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Postoperative organ failures commonly occur after major abdominal surgery and substantially increase the utilization of resources and the costs of care, and are favored by tissue hypoxia. Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
High-Risk Surgical Patients
What is being tested?
Increase oxygen extraction rate
Type of treatment
Surgery or procedure
How many people
130 participants
Where
1 siteItaly
Study dates
May 1995to Dec 1996
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • high risk surgical patients requiring major abdomina surgery

Who cannot join

  • age below 16 years, preexistent neurologic, or malignant haematologic diseases

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Azienda Ospedaliera Umberto I - U.O. Anestesia e Rianimazione Clinica

    Ancona, Ancona, 60020

Other trials in Italy

About this study

Official title: Goal-Directed Intraoperative Therapy Reduces Morbidity and Length of Hospital Stay in High Risk Surgical Patients

Postoperative organ failures commonly occur after major abdominal surgery and substantially increase the utilization of resources and the costs of care, and are favored by tissue hypoxia. A therapeutic strategy designed to detect and reverse tissue hypoxia, as diagnosed by an increase of oxygen extraction over a pre-defined threshold could decrease the incidence of organ failures.

Read the detailed description

The development of postoperative organ failures severely affects the prognosis of surgical patients, and substantially increases the utilization of resources and the costs of care. The presence of tissue hypoxia is particularly common and likely results from an impairment of the adaptive mechanisms of myocardial function, leading to an inappropriately low cardiac output and from the effects of inflammatory mediators. Importantly, tissue hypoxia can be detected early. Indeed, hypoxic tissues will compensate the hypoperfusion by increasing oxygen extraction (O2ER) over a threshold value, a change that will also be reflected by a decreased venous oxygen saturation, and if uncompensated by lactic acidosis. Hence, the use of oxygen extraction calculated from arterial and central venous oxygen saturation as a therapeutic goal is appropriate to monitor goal-directed hemodynamic strategies, as it reflects the balance between oxygen delivery and consumption. In place of O2ER or its surrogate, mixed venous oxygen saturation, the use of oxygen-derived values measured in central blood drawn from the routinely placed central line, in place of pulmonary artery catheter, may represent a valuable alternative. Indeed, recent evidence suggests that a multifaceted goal-directed strategy, including fluid challenge, blood transfusion and inotropes titrated to keep central venous oxygen saturation higher than a predetermined threshold of 70% was associated with decreased mortality and rate of organ failures when applied from the early phase of septic shock or severe sepsis. The aim of the present multicentre prospective randomized study was to compare the outcomes of patients randomized to a conventional management or to a therapeutic strategy guided by O2ER estimate (O2ERe) calculated from the arterial oxygen saturation and the central venous saturation ScvO2. Specifically, we hypothesized that the use of a goal-directed protocol aimed at maintaining the O2ERe below a previously defined "critical" (able to discriminate survivors from non-survivors) value of 26.7% during surgical interventions in high-risk patients will reduce the rate of postoperative organ failures, hospital length of stay and mortality, as compared with the standard management based on the monitoring of mean arterial pressure, central venous pressure and urine output.

High Risk surgical patients scheduled for elective abdominal extensive surgery were eligible. After enrollment, the patients were randomized to one of the two groups of treatment (A or B) by a phone system on a 24-hour-a-day, 7-day-a-week basis. Randomization was based on a permuted-block algorithm, allowing stratification for each center. The exclusion criteria from the study were : age below 16 years, preexistent neurologic, or malignant haematologic diseases.

In preparation for surgery, the patients were equipped with central and peripheral venous and arterial catheters. Standard monitoring included continuous recording of electrocardiography; body temperature, heart rate, pulse oxymetry and arterial blood pressure. Central venous pressure, ScvO2 , arterial blood gases, lactate concentration, body temperature, and urine output were recorded hourly. Hemoglobin concentration was measured when deemed necessary by the anesthesiologist. For the purpose of the study, blood gases measured on arterial and central venous samples, arterial lactate and O2ERe (SaO2-ScvO2/SaO2 [SaO2 : arterial oxygen saturation, ScvO2 : central venous saturation]) were recorded after induction of anesthesia (T0), hourly after cutaneous incision (T1a-f), throughout surgery, during the first 6 hours of the postoperative period (T2a-f) and on postoperative day 1.

In both groups, the patients were managed to achieve predefined standard goals, i.e. a meen arterial pressure (MAP) >80 mmHg and an urine output > 0.5ml/kg/h. The patients of the "protocol group" (Group A) were managed to keep O2ER below 26.7%, following algorithms detailed in figure 1. In brief, a fluid challenge (colloids 250-1000 ml infused over 30 min to restore central venous pressure to at least 10 mmHg), dobutamine (incremental doses of 3 µg/kg/min up to 15 µg/kg/min) and/or packed red cells (in cases of hemoglobin below 10 g/dl or intraoperative hemorrhage > 1000 ml) could be administered. There was no specific requirement regarding the type of anesthesia in any of the groups.

Being tested
Increase oxygen extraction rate

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Increase oxygen extraction rateProcedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. reduction of patients with postoperative organ failure

Secondary outcomes (1)
  1. reduction of length of hospital stay

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2005 (estimated)
  2. Study startMay 1995
  3. Study completionDec 1996

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
130 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00254150
Sponsor's protocol ID
O2ER GDT
Status last verified
Apr 1995
First submitted
14 Nov 2005
Last updated
15 Nov 2005
Results posted
No

Publications

  • Donati A, Loggi S, Preiser JC, Orsetti G, Munch C, Gabbanelli V, Pelaia P, Pietropaoli P. Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk surgical patients. Chest. 2007 Dec;132(6):1817-24. doi: 10.1378/chest.07-0621. Epub 2007 Oct 9.

    PubMed 17925428

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Increase oxygen extraction rate in people with High-Risk Surgical Patients, run by Università Politecnica delle Marche at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Nov 2005. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

reduction of patients with postoperative organ failure. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00254150, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2005.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in